Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma – Yahoo Finance

  • Whatsapp

Is the fossil fuel recovery real, or a stepping stone to a fossil-free future? Register now for our 11/17 webinar at 2PM ET

UV1 vaccine combined with ipilimumab induced immune responses in 91% of melanoma patients
Immune responses persist and are detectable up to 5 years
Oslo, November 9, 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage leader in immune stimulatory vaccines for cancer, announces data showing that the Company’s universal cancer vaccine UV1 in combination with ipilimumab induces dynamic, multi-functional T cell responses in patients with melanoma, with the potential for protection of 5 years or more. The data will be presented as a poster at the Society For Immunotherapy of Cancer’s 36th Annual Meeting (SITC2021) being held in Washington, DC, USA November 10-14, 2021.
The SITC2021 data are from an early Ultimovacs’ Phase I/IIa study of UV1 with the checkpoint inhibitor ipilimumab in twelve patients with melanoma (NCT02275416). They show that the drug combination induces a T cell immune response in 91% of patients, and that the response can persist as long as 5 years (the end of the study period). The UV1-ipilimumab combination induces T cells that are polyfunctional and produce multiple effector cytokines such as interferon-gamma and TNF-alpha essential for a robust anti-tumor response. Tumor biopsies revealed an influx of tumor-infiltrating lymphocytes (TIL) in patients who responded well to treatment. The finding is a positive early signal in a broader R&D program aimed at documenting the mechanistic effects of UV1.
“These are pleasing and clear data. The UV1-induced T cells continue to respond dynamically to the presence of antigen over a prolonged period. The longevity of the induced immune response and the persisting proliferative capacity of the T cells provide optimism for UV1’s potential to provide long-term clinical impact for the patients.” said Gustav Gaudernack, Chief Scientific Officer of Ultimovacs. “Ultimovacs is delighted to be able to share these data with the scientific and clinical community at SITC. As a company, we remain committed to progressing UV1 in our ongoing Phase II clinical studies.”
Ultimovacs’ poster is entitled: “The Synthetic Long Peptide Cancer Vaccine UV1 in Combination with Ipilimumab Induces a CD4+ Th1 Anti-hTERT Immune Response and an Inflammatory Tumor Microenvironment in Patients with Melanoma”. The poster presentation will be made available via the Ultimovacs website at November 12, 2021.
UV1 is being investigated in combination with checkpoint inhibitors in Phase II trials covering advanced malignant melanoma, ovarian cancer, head and neck squamous cell carcinoma, malignant pleural mesothelioma, and non-small cell lung cancer (NSCLC).

Read More

In total, the five Phase II trials will enroll more than 650 patients at nearly 100 clinical centers across 15 countries. The U.S. FDA recently granted Fast Track designations to the combinations of UV1 with ipilimumab and UV1 with pembrolizumab in the treatment of advanced malignant melanoma.
About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types in combination with other immunotherapies. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: [email protected]
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: [email protected]
Phone: +47 482 48632
Mary-Ann Chang, LifeSci Advisors
Email: [email protected]
Phone: +44 7483 284 853
This announcement was published by Joachim Midttun, Finance Manager at Ultimovacs ASA, on November 9, 2021 at 14:00 CET.

INEO Tech Corp. (TSXV: INEO) (OTCQB: INEOF) (the "Company" or "INEO"), an innovative provider of location-based digital advertising, analytics and loss prevention solutions for retailers, today announced it has entered into a market-making agreement with Independent Trading Group ("ITG") pursuant to which ITG has agreed to provide market-making services to the Company in accordance with the policies of the TSX Venture Exchange (the "TSXV") and applicable laws.
Until late 2020, Ocugen (NASDAQ: OCGN) was an under-the-radar biotech company focusing on developing gene therapies targeting eye disease. Then along came Bharat Biotech. Bharat wanted a partner to help get Covaxin into the U.S. market.
Novavax (NVAX) is getting some momentum for its two-dose COVID-19 vaccine, starting with a series of emergency use fillings globally and the first authorization in Indonesia this month. The company is on track to file with the U.S. Food and Drug Administration (FDA) by the end of the year, and has already called for a meeting with the agency to move forward, according to CEO Stanley Erck. Erck told Yahoo Finance Live on Wednesday that the company expects to hear back from the FDA "very soon" and believes Novavax could receive up to five authorizations in the coming 6-8 weeks globally. But a majority of its distribution of actual doses is likely to start at the beginning of 2022.
Pfizer (NYSE: PFE) has won the title of leader when it comes to coronavirus vaccine prevention. Now, Pfizer may be about to claim leadership in another blockbuster area: coronavirus treatment. Data were so strong that an independent monitoring committee recommended Pfizer stop enrolling patients in the trial — and seek regulatory authorization.
Compass Pathways plunged, despite reporting that a strong dose of a psilocybin-based drug helped reduce depression.
Is AbbVie stock a buy as shares retake their key moving averages on strong third-quarter earnings? Is ABBV stock a buy right now?
The drug is approved in Europe and China to treat chronic kidney disease patients with anemia, but likely will need to undertake another clinical trial in the United States to appease the Food and Drug Administration.
The company's revenue was $126.7 million, compared with only $1.4 million year over year, with most of the increase from collaboration revenue from Seres' co-commercialization license agreement with Nestlé Health Science. The improved financial numbers were only part of the story. On Wednesday, Seres said it had established a collaboration with Swiss pharmaceutical company Bacthera to manufacture SER-109, Seres' lead therapy to treat recurrent Clostridioides difficle infection (rCDI).
The good news is that shares of the messenger RNA (mRNA) vaccine maker have skyrocketed over 1,100% since the beginning of 2020. The bad news is that Moderna has given up a lot of its gains with the stock plunging close to 50% below its high from earlier this year. Two Motley Fool contributors have different takes on Moderna.
Vermont has seen COVID-19 cases surge to their highest levels in the pandemic. Here's what health officials think is happening.
When you reach retirement age, Medicare insurance offers basic medical insurance protection for your health needs. However, this coverage is basic and does not cover all of the costs for covered medical services and supplies. Medicare supplemental insurance policies are … Continue reading → The post Average Cost of Medicare Supplemental Insurance appeared first on SmartAsset Blog.
After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc's Aduhelm, saying that its medication would be priced competitively. Bill Anderson, head of pharmaceuticals at Roche, did not provide pricing details for the company's treatment for the lethal brain-wasting disease, but indicated in an interview that it could be priced below Aduhelm's $56,000-a-year cost.
The average cost of employer health coverage for a family plan passed $22,000 this year, according to a Kaiser Family Foundation survey, rising at a rate that indicates the pandemic had little impact on the total expense.
Nearly 90% of U.S. adults 65 and older currently take at least one prescription medication. More than half (54%) of American seniors take four or more. For the millions with a Medicare drug plan, Open Enrollment may be the one chance to review and find the best coverage for the coming year. Some 24 million Americans have a stand-alone Medicare prescription drug (Part D) plan. Depending on where you live there can be between 10 and 30 different plans available. Comparing your 2022 plan options no
Over the past year, shares of Beam Therapeutics (NASDAQ: BEAM) have soared over 174% higher. This is the firm founded and still run by Cathie Wood, one of the world's most famous investors. Beam Therapeutics is pioneering the use of a new base editing technique in the development of new gene therapies.
Tori Geib successfully fought for changes to the way cancer was treated in Ohio. She brought national attention to what it's like to live with cancer.
There’s some good news for ice cream and cheese lovers.
With a few exceptions for emergency or urgent care, Medicare plans will only cover you within the U.S. and its territories. But should you maintain your coverage when you move abroad? Expert Ron Elledge answers some common questions.
Nvidia's technology is being used to develop new cancer treatments and medical devices.


Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *